Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Share News (IQAI)

Share Price Information for IQ-AI (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.30
Bid: 1.20
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.20 (16.667%)
Open: 1.30
High: 1.40
Low: 1.30
Prev. Close: 1.30
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

Thu, 23rd May 2024 21:08

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Celadon Pharmaceuticals PLC - pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines - Ships two different medical cannabis products to US, its first international commercial supply. "The American business is a supplier to a number of different US government departments, and this initial sale has the potential to grow into a material source of additional revenue. The product has been supplied from the company's UK facility," it adds.

----------

Oxford BioDynamics PLC - Oxford, England-based biotech company - Teams with Goodbody Clinic to offer nationwide access to EpiSwitch prostate screening test "at all its locations across the UK, supported by its network of GPs". Oxford BioDynamics Chief Executive Officer George Thomas adds: "The rapid EpiSwitch PSE test can significantly enhance the accuracy of detecting prostate cancer, allowing us to provide better care and peace of mind to men throughout the whole country. We are always looking to advance our commitment to accessible, high-quality healthcare by combining the latest innovations like the PSE with access to Goodbody's convenient clinics and home testing solutions."

----------

IQ-AI Ltd - London-based medical services company - Says cancer centre located on the eastern seaboard of US subscribes to IB Nimble to optimise care for patients suffering from brain cancer. IQ-AI adds: "Treatment decisions require timely discussions to provide optimal personalized care. IB Nimble is integral to this effort as it facilitates real-time discussion and collaboration amongst all the multidisciplinary specialists. The mobile app will be used to improve the quality of care by, for example, improving patient-reported outcomes, avoiding unnecessary hospital admissions, and decreasing the length of hospital stays."

----------

Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Enters deal for new project to develop an antibody based therapeutic with existing client, a US biotech firm. "This contract is separate and in addition to the USD650,000 follow-on project currently being undertaken for the client," it adds. Says new deal is "centred on combatting a chronic debilitating disease in humans" and is expected to amount to GBP200,000 in revenue for Fusion.

----------

PipeHawk PLC - Hampshire, England-based provider of technology for highways and for the automotive, rail and aerospace industries - QM Systems subsidiary awarded contract with "major aluminium casting provider" to deliver leak testing systems for testing of aluminium diecast components. Deal is worth GBP1.2 million and will take nine months to deliver. Chair Gordon Watt says: "This contract award represents a brand-new client for QM, however a subsidiary of the customer has been a long-standing partner for QM for many years. Over these years QM have delivered a significant number of similar systems to the customer's subsidiary and continues to do so. We are excited to welcome this new customer to QM's continually expanding partner base."

----------

Crystal Amber Fund Ltd - invests in small and mid-cap UK equities - Will continue share buyback programme for the period to June 30. Since December 8, GBP7.5 million has been utilised in the programme. It now plans to continue buybacks up to GBP2.5 million.

----------

ADM Energy PLC - natural resources investing company - Updates on recent activity of investee JKT Reclamation. ADM had acquired an interest in JKT parent SW Oklahoma Reclamation LLC in April. ADM notes a mixing tank and two new fluid pumps have been leased for the reclamation site. "This new equipment will assist in increasing the processing capacity of the JKT's reclamation facility in Wilson, Oklahoma and is scheduled to be delivered and installed in early June 2024," ADM says. "Following delivery and installation of the new equipment, JKT is targeting to expand production to 3,500 to 4,000 barrels of oil per month. JKT has also entered into a short-term working capital facility that allows for short-term advances against oil sold, payable within 90 days, at a cost of 1.75% per month on the quantum of funds borrowed. The facility will provide JKT the short term funds required to expedite its growth."

----------

Pharos Energy PLC - oil and gas exploration and production company with assets in south east Asia and the Middle East - Says entered 2024 on "strong operational and financial position", and output in first four months of year in line with expectations. Chief Executive Officer Jann Brown adds: "In Egypt, we are preparing to drill in both El Fayum and NBS later this year, while in Vietnam, preparations are well advanced for our 2H two-well drilling programme on TGT. I am pleased with the recent progress made on the licence extension discussions on both TGT and CNV, while in Egypt we are pursuing a consolidation of our two concessions into one to deliver a number of benefits. On Blocks 125 & 126 in Vietnam, we are progressing options to secure a drilling slot for Prospect A, the key catalyst for parties interested in farming in to these licences."

----------

Afentra PLC - upstream oil and gas company focused on acquiring mature production and development assets in Africa - Seals acquisition of 12% non-operating interest in Block 3/05 and a 16% non-operating interest in Block 3/05A offshore Angola. Pays USD28.4 million cash.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
14 Jun 2024 14:32

IQ-AI team begins defining phase 2 protocol for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, which could be a therapeutic agent for cancer.

Read more
20 May 2024 11:16

IQ-AI subsidiary gets second FDA rare paediatric disease designation

(Alliance News) - IQ-AI Ltd on Monday said its subsidiary, Imaging Biometrics LLC, received a second rare paediatric disease designation by the US Food & Drug Administration for its IB-003 lead drug candidate oral gallium maltolate.

Read more
17 May 2024 17:39

TRADING UPDATES: Ingenta trades in line; Triple Point Social NAV up

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
10 May 2024 15:14

IQ-AI subsidiary gets rare paediatric disease designation FDA

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary, Imaging Biometrics LLC, has been granted rare paediatric disease designation by the US Food & Drug Administration for its lead drug candidate, IB-003, or gallium maltolate for the treatment of ATRT.

Read more
2 May 2024 15:45

EARNINGS AND TRADING: Trident Royalties swings to profit

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more
10 Jan 2024 11:48

IQ-AI falls after subsidiary notes launch of treatment access scheme

(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate.

Read more
19 Dec 2023 17:00

IQ-AI firm gets US FDA fast-track status for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Tuesday said the US Food & Drug Administration has granted 'fast-track" designation for oral gallium maltolate, which is its subsidiary Imaging Biometrics LLC's therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma.

Read more
5 Dec 2023 11:49

IQ-AI stock rises on positive interim results from glioblastoma trial

(Alliance News) - IQ-AI Ltd on Tuesday reported positive results from Phase 1 of an on-going study for its investigational monotherapy oral gallium maltolate.

Read more
8 Nov 2023 12:04

IQ-AI says Imaging Biometrics submits paediatric rare disease request

(Alliance News) - IQ-AI Ltd on Wednesday said its wholly-owned subsidiary Imaging Biometrics LLC has submitted a paediatric rare disease request to the US Food & Drug Administration for its gallium maltolate therapy.

Read more
18 Oct 2023 17:11

IN BRIEF: IQ-AI subsidiary "central" to "landmark" brain cancer study

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Notes its wholly-owned subsidiary, Imaging Biometrics LLC (IB), has announced the results of a "landmark" study. Says the study represents the first large-scale characterization of the invasive tumour margins of high-grade glioma using multi-regional genomic/transcriptomic sequencing with spatially matched MRI measurements in glioma. High-grade glioma is a deadly brain cancer. Explains that Imaging Biometrics' IB Neuro's dynamic susceptibility contrast magnetic resonance imaging software was central to the study.

Read more
9 Oct 2023 12:09

IN BRIEF: IQ-AI subsidiary wins orphan drug designation from US FDA

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Wholly-owned subsidiary Imaging Biometrics LLC is granted an orphan drug designation from the US Food & Drug Administration for gallium maltolate for the treatment of atypical teratoid rhabdoid tumour. Notes this is the second orphan designation granted to gallium maltolate this year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.